The results of a large network meta-analysis throw additional support for a paradigm shift in how dual antiplatelet therapy (DAPT) should be maintained after PCI with drug-eluting stents, researchers say. “We suggest that for patients who are not high risk, most of the time short-term DAPT for less than six months followed by P2Y12 inhibitor monotherapy is the way to go,†said Safi U. Khan, MD (West Virginia University, Morgantown, WV), lead author of the study.
|